Pre-Conference Workshop Discussions Day

Workshop A

Establishing Early Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B

While current direct acting antiviral therapies have been effective in controlling viral replication and limiting progression to cirrhosis, HBsAg loss is rare and lifelong therapy is often required. Novel immunotherapeutic approaches and combination therapy will be an essential strategy to improve efficacy and the likelihood of HBV functional cure. However, as strategy moves away from monotherapy, early industry partnerships will be critical to future approaches.

Join this workshop to participate in the industry forum dedicated to driving successful industry collaborations in combination therapy for chronic HBV.

Highlights include:

• Attracting other partners into clinical programs to develop early partnerships for combination therapies

• Assessing synergistic mechanisms of action to optimize drug develop for chronic HBV

• Looking to the future: forging industry collaboration with immune modulators and antivirals

Luisa Stamm Assembly

Luisa Stamm
Chief Medical Officer
Assembly Biosciences

Jeysen Yogaratnam Drug Farm

Jeysen Yogaratnam
Chief Medical Officer
Drug Farm

David Anderson VBI

David Anderson
Chief Scientific Officer
VBI Vaccines

Andrew Vaillant Replicor

Andrew Vaillant
Chief Scientific Officer

Workshop B

Mechanisms, Regulation & Therapeutic Potential: Targeting cccDNA to Attain HBV Cure

As elimination or transcriptional silencing of cccDNA is essential for HBV cure, clarification of the mechanisms underlying cccDNA formation and regulation will be crucial to understanding the possible strategies to eradicate HBV through targeting cccDNA and developing beyond functional cure. Small interfering RNA has the potential to transform approaches to effectively targeting HBV and silencing the viral genome and may represent the next step in the race to a true cure.

Join this workshop to keep up with the latest updates in targeting cccDNA.

Highlights include:

• Characterizing the formation and persistence of the HBV covalently closed circular DNA

• Examining resistance to current antiviral treatments and potential therapeutic strategies for targeting cccDNA

• Assessing progress in achieving and maintaining silencing of cccDNA transcription in vivo

Thomas Baumert

Thomas Baumert
Professor of Medicine,
Head Inserm Research
Institute, Chair
Hepatology University Hospital

Andrew Vaillant Replicor

Andrew Vaillant
Chief Scientific Officer

Alexander Ploss Princeton

Alexander Ploss
Associate Professor of
Molecular Biology
Princeton University

Workshop C

The Next Strategic Step for Virology: Delineating Strategies to Drive Progress in Protection Against RSV

Despite significant advances in defining therapeutic targets for respiratory syncytial virus (RSV), a lack of reliable biomarkers and reflective animal models has littered research with clinical setbacks causing RSV to become a leading cause of global infant morbidity.

As a decrease in viral load does not necessarily provide clinical benefit, what is the next step in accurately and consistently predicting disease severity and monitoring the efficacy of new therapeutic strategies?

Highlights include:

• Progressing beyond the murine model: exploring rodents, mustelids, and non-human primates to elucidate different features of the pathology caused by the hRSV infection and understand novel therapies

• Identifying useful biomarkers to predict the clinical course of the disease and monitor efficacy

• Correlating a reduction in viral load with a reduction in symptoms

• Immunogenicity and protective efficacy of RSV G central conserved domain vaccine alone or with a pre-F nanoparticle


Linong Zhang Sanofi

Linong Zhang

Michael Kishko Sanofi

Michael Kishko
Principal Scientist,
Global Antigen Design